Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Penile Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
0 drugs · 0 active trials
no drug at this stage
0 drugs · 0 active trials
no drug at this stage
Data updated 6 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Nivolumab | Phase 2 | Phase 2 | 5 | 1 | 0 | 5 | 0 | — | — | Jul 22, 2015 |
| Ipilimumab | Phase 2 | Phase 2 | 4 | 1 | 0 | 4 | 0 | — | — | Jul 22, 2015 |
| Avelumab | Phase 2 | Phase 2 | 3 | 1 | 0 | 4 | 0 | — | — | Sep 1, 2017 |
| Cabozantinib | Phase 2 | Phase 2 | 3 | 1 | 0 | 4 | 0 | — | — | Jul 22, 2015 |
| Aldesleukin | Phase 2 | Phase 2 | 2 | 2 | 0 | 4 | 0 | — | — | Apr 13, 2012 |
| Pembrolizumab | Phase 2 | Phase 2 | 2 | 1 | 0 | 4 | 0 | — | — | Aug 15, 2016 |
| Atezolizumab | Phase 2 | Phase 2 | 2 | 1 | 0 | 3 | 0 | — | — | Mar 3, 2017 |
| Enfortumab Vedotin | Phase 2 | Phase 2 | 2 | 2 | 0 | 2 | 0 | — | — | Dec 21, 2023 |
| Cyclophosphamide | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | Apr 13, 2012 |
| Fludarabine | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | Apr 13, 2012 |
| Niraparib | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Aug 29, 2017 |
| Amivantamab | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | 2026-11 |
| Bevacizumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Mar 3, 2017 |
| Carboplatin/Paclitaxel Regimen | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Aug 13, 2024 |
| Cemiplimab | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | 2025-12 |
| Dostarlimab | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Dec 28, 2022 |
| Sacituzumab Govitecan | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Aug 1, 2024 |
| Afatinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2015-10 |
| Cetuximab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2016-02 |
| Docetaxel | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2004-10 |
| Durvalumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Nov 14, 2018 |
| Fluorouracil | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Aug 29, 2017 |
| Irinotecan | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2003-06 |
| Nab-paclitaxel | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Aug 12, 2020 |
| Nimotuzumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Aug 12, 2020 |
| Pazopanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2015-01 |
| Retifanlimab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 28, 2020 |
| Rigosertib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2013-03 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.